ArticleFrontiers in cell and developmental biology2022
SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma.
Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- CTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucoma.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Lapatinib induces ferroptosis in osteosarcoma via the SLC1A5-GPX4 axis.Journal of bone oncology · 2026Article
- Ferroptosis regulator NOX1 acts a diagnostic biomarker and mediates disease progression with the transcriptional regulation of STAT3 in glaucoma.Indian journal of ophthalmology · 2026Article
- Metabolotheranostics of pancreatic cancer by targeting choline, glutamine, and glucose transporters with photoimmunotherapy.Npj imaging · 2026Article
- Identification and evaluation of glutamine-related gene characteristics based on multi-omics to predict the prognosis of patients with colorectal cancer.Journal of translational medicine · 2026Article
- ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3.Scientific reports · 2025Article
- Article
- A Review on the Role of Human Solute Carriers Transporters in Cancer.Health science reports · 2025Article
- The expression of mercaptopyruvate sulfurtransferase serves as a potential biomarker for prognostic stratification and immunotherapy in certain cancers.Frontiers in oncology · 2025Article
- Identification of biomarkers associated with inflammatory response in Parkinson's disease by bioinformatics and machine learning.PloS one · 2025Article
- Identification of biological significance of different stages of varicose vein development based on mRNA sequencing.Scientific reports · 2024Article
- The disruption of NEAT1-miR-125b-5p-SLC1A5 cascade defines the oncogenicity and differential immune profile in head and neck squamous cell carcinoma.Cell death discovery · 2024Article
- Glutamine transporters as effective targets in digestive system malignant tumor treatment.Oncology research · 2024Review
- Bioinformatics analysis of potential key ferroptosis-related genes involved in tubulointerstitial injury in patients with diabetic nephropathy.Renal failure · 2023Article
- Article
- The Regulation of Ferroptosis by Noncoding RNAs.International journal of molecular sciences · 2023Review
- Ferroptosis-Related Gene SLC1A5 Is a Novel Prognostic Biomarker and Correlates with Immune Microenvironment in HBV-Related HCC.Journal of clinical medicine · 2023Article
- Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.BMC cancer · 2023Article
- Ferroptosis regulator NOS2 is closely associated with the prognosis and cell malignant behaviors of hepatoblastoma: a bioinformatic andFrontiers in oncology · 2023Article
- PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell death-based drug sensitivity stratification.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.